🇺🇸 FDA

Company profile · Sponsor

PURPLE

PURPLE BIOTECH LTD.

PPBT · NYSE biotech REHOVOT, L3, USA
Pipeline
3
Drugs
1
Patents
3

Quick answer

PURPLE (PPBT) is a biotech company. headquartered in REHOVOT, L3, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 1 drug, and 3 patents to this profile..

Company facts

Ticker PPBT
Exchange NYSE
Company type biotech
Headquarters REHOVOT, L3, USA
SEC CIK 0001614744

Pipeline (3)

Search pipeline →

  1. CM-24 and Nivolumab - Dose Escalation

    PURPLE

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  2. NT219

    PURPLE

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  3. NT219

    PURPLE

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. amlodipine besylate

    AMLODIPINE BESYLATE

    ORAL approved

Patents (3)

Search patents →

  1. US 12378277

    SGLTS/DPP4 inhibitor and application thereof

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11752184

    Bioactive concentrates and uses thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11484523

    Compositions for prevention and treatment of symptoms associated with alcohol consumption

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is PURPLE?

PURPLE (PPBT) is a biotech company. headquartered in REHOVOT, L3, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 1 drug, and 3 patents to this profile..

What pipeline programs does PURPLE sponsor?

We track 3 ClinicalTrials.gov-linked programs for PURPLE, including CM-24 and Nivolumab - Dose Escalation and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does PURPLE company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.